EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacokinetic and safety profile of PT109B, a novel multi-targeted compound against Alzheimer's disease

Yufeng Wu, Yang Yang, Jingyu Liu, Yagang Li, Rongbiao Pi, Yu Ren, Tianyang Jiang, Yuran Wang, Guoping Zhong

European Journal of Pharmaceutical Sciences · 2023

DOI: 10.1016/j.ejps.2023.106532 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmaceutical Sciences, 2023. Verfasst von Yufeng Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, Guangdong 510000, China; Guangdong Provinci…. Hauptthemen laut MEDLINE: Alzheimer Disease, Isoquinolines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PT109B, 5-(1,2-dithiolan-3-yl)-N-((1r,4r)-4-(isoquinolin-5-ylamino) cyclohexyl) pentanamide, a novel compound structurally related to Fasudil, has been reported as a promising candidate for treating Alzheimer's disease. To investigate the pharmacokinetics and acute toxicity of PT109B in rodents, we first developed and validated a UPLC-MS/MS analytical method to detect PT109B concentration in the biological matrix. The proposed method could separate and quantify the PT109B with good precision and accuracy. The pharmacokinetic results showed that the concentrations of PT109B in rat plasma increased with the dose, but not proportionally. Meanwhile, the double-peak phenomenon disappeared when decreasing the oral administration dosage. In addition, we found that PT109B could be detected in the central nervous system, and highly distributed in the liver and kidney. At the same time, the gender difference of PT109B in rats was observed, and the exposure of PT109B in female rats was significantly higher than that in male rats after oral administration. Finally, we found that oral administration of 750 mg/kg PT109B to C57 BL/6 mice caused significant liver injury in females, which was specifically manifested as hepatomegaly, increased liver coefficient, and hepatocyte ballooning. However, no significant damage was observed in other organs, which may be related to the distribution of PT109B in the liver. In summary, we first established a UPLC-MS/MS method for the analysis of PT109B in a biological matrix and described the characteristics of pharmacokinetics, and acute toxicity of PT109B in rodents, providing a sufficient pharmacokinetic basis for further study of PT109B.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseIsoquinolinesAnimalsMaleFemaleRats, Sprague-DawleyTandem Mass SpectrometryMiceRatsAdministration, OralTissue Distribution

Stichwörter der Autor:innen

Acute toxicityPT109BPharmacokineticTissue distributionUPLC-MS/MS

Substanzen

Isoquinolines

Autor:innen und Institutionen

  • Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, Guangdong 510000, China; Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, School of Pharmac…
  • School of Medicine, Shenzhen campus of Sun Yat-sen University, Sun Yat-sen University, Shenzhen, Guangdong 518107, China.

Zitieren

APA

Wu, Y., Yang, Y., Liu, J., Li, Y., Pi, R., Ren, Y., Jiang, T., Wang, Y., & Zhong, G. (2023). Pharmacokinetic and safety profile of PT109B, a novel multi-targeted compound against Alzheimer's disease. European Journal of Pharmaceutical Sciences. https://doi.org/10.1016/j.ejps.2023.106532

Vancouver

Wu Y, Yang Y, Liu J, Li Y, Pi R, Ren Y, et al. Pharmacokinetic and safety profile of PT109B, a novel multi-targeted compound against Alzheimer's disease. European Journal of Pharmaceutical Sciences. 2023. doi:10.1016/j.ejps.2023.106532

BibTeX
@article{Wu2023,
  author = {Wu, Yufeng and Yang, Yang and Liu, Jingyu and Li, Yagang and Pi, Rongbiao and Ren, Yu and Jiang, Tianyang and Wang, Yuran and Zhong, Guoping},
  title = {Pharmacokinetic and safety profile of PT109B, a novel multi-targeted compound against Alzheimer's disease},
  journal = {European Journal of Pharmaceutical Sciences},
  year = {2023},
  doi = {10.1016/j.ejps.2023.106532}
}
Kostenlos starten →